1709 related articles for article (PubMed ID: 16781284)
21. Cardiac complications in childhood cancer survivors treated with anthracyclines.
Franco VI; Lipshultz SE
Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
[TBL] [Abstract][Full Text] [Related]
22. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations.
Sparano JA
Semin Oncol; 1998 Aug; 25(4 Suppl 10):66-71. PubMed ID: 9768827
[TBL] [Abstract][Full Text] [Related]
23. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines.
Silber JH; Cnaan A; Clark BJ; Paridon SM; Chin AJ; Rychik J; Hogarty AN; Cohen MI; Barber G; Rutkowski M; Kimball TR; Delaat C; Steinherz LJ; Zhao H
J Clin Oncol; 2004 Mar; 22(5):820-8. PubMed ID: 14990637
[TBL] [Abstract][Full Text] [Related]
24. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
Lopez M; Vici P
Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
[TBL] [Abstract][Full Text] [Related]
25. [Dexrazoxane. Current status and prospectives of cardiotoxicity of chemotherapy].
Lopez M
Clin Ter; 1999; 150(1):37-49. PubMed ID: 10367544
[TBL] [Abstract][Full Text] [Related]
26. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity.
Herman EH; Ferrans VJ
Semin Oncol; 1998 Aug; 25(4 Suppl 10):15-21. PubMed ID: 9768819
[TBL] [Abstract][Full Text] [Related]
27. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.
Lipshultz SE; Colan SD; Gelber RD; Perez-Atayde AR; Sallan SE; Sanders SP
N Engl J Med; 1991 Mar; 324(12):808-15. PubMed ID: 1997853
[TBL] [Abstract][Full Text] [Related]
28. [ACE inhibitors in the treatment of ventricular dysfunction caused by cardiotoxic cytostatics].
Mladosievicová B
Ceska Slov Farm; 2004 Mar; 53(2):55-60. PubMed ID: 15095572
[TBL] [Abstract][Full Text] [Related]
29. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity.
Conklin KA
Integr Cancer Ther; 2005 Jun; 4(2):110-30. PubMed ID: 15911925
[TBL] [Abstract][Full Text] [Related]
30. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
Lipshultz SE; Scully RE; Lipsitz SR; Sallan SE; Silverman LB; Miller TL; Barry EV; Asselin BL; Athale U; Clavell LA; Larsen E; Moghrabi A; Samson Y; Michon B; Schorin MA; Cohen HJ; Neuberg DS; Orav EJ; Colan SD
Lancet Oncol; 2010 Oct; 11(10):950-61. PubMed ID: 20850381
[TBL] [Abstract][Full Text] [Related]
31. Anthracycline-related cardiotoxicity in childhood cancer survivors.
Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
[TBL] [Abstract][Full Text] [Related]
32. The effect of dexrazoxane for clinical and subclinical cardiotoxicity in children with acute myeloid leukemia.
Sánchez-Medina J; Gonzalez-Ramella O; Gallegos-Castorena S
J Pediatr Hematol Oncol; 2010 May; 32(4):294-7. PubMed ID: 20404753
[TBL] [Abstract][Full Text] [Related]
33. Anthracycline cardiotoxicity in children.
Kremer LC; Caron HN
N Engl J Med; 2004 Jul; 351(2):120-1. PubMed ID: 15247351
[No Abstract] [Full Text] [Related]
34. [Severe heart failure in consequence of late anthracycline-induced cardiotoxicity--case report].
Urbanová D; Bubanská E; Hrebík M; Mladosievicová B
Klin Onkol; 2009; 22(1):34-7. PubMed ID: 19534438
[TBL] [Abstract][Full Text] [Related]
35. [Cardiac toxicity in cancer therapy].
Łacko A; Włodarska I; Zymliński R; Mazur G; Wróbel T; Gisterek I
Pol Merkur Lekarski; 2002 Jul; 13(73):79-85. PubMed ID: 12362515
[TBL] [Abstract][Full Text] [Related]
36. Overview and historical development of dexrazoxane.
Hellmann K
Semin Oncol; 1998 Aug; 25(4 Suppl 10):48-54. PubMed ID: 9768824
[TBL] [Abstract][Full Text] [Related]
37. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
[TBL] [Abstract][Full Text] [Related]
38. Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.
Elbl L; Hrstkova H; Tomaskova I; Michalek J
Support Care Cancer; 2006 Feb; 14(2):128-36. PubMed ID: 16034614
[TBL] [Abstract][Full Text] [Related]
39. Clinical heart failure during pregnancy and delivery in a cohort of female childhood cancer survivors treated with anthracyclines.
van Dalen EC; van der Pal HJ; van den Bos C; Kok WE; Caron HN; Kremer LC
Eur J Cancer; 2006 Oct; 42(15):2549-53. PubMed ID: 16919450
[TBL] [Abstract][Full Text] [Related]
40. Low anthracyclines doses-induced cardiotoxicity in acute lymphoblastic leukemia long-term female survivors.
Amigoni M; Giannattasio C; Fraschini D; Galbiati M; Capra AC; Madotto F; Cesana F; Jankovic M; Masera G; Mancia G
Pediatr Blood Cancer; 2010 Dec; 55(7):1343-7. PubMed ID: 20589666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
